MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings
About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.
Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 董事会薪酬与考核委员会工作细则（草案） | 2026-04-07 | Chinese | |
| 董事提名政策（草案） | 2026-04-07 | Chinese | |
| 董事会战略委员会工作细则（草案） | 2026-04-07 | Chinese | |
| 股东通讯政策（草案） | 2026-04-07 | Chinese | |
| 迈威生物关于修订H股发行后适用的《公司章程》及公司部分治理制度的公告 | 2026-04-07 | Chinese | |
| 股息政策（草案） | 2026-04-07 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44579653 | 董事会薪酬与考核委员会工作细则（草案） | 2026-04-07 | Chinese | ||
| 44579649 | 董事提名政策（草案） | 2026-04-07 | Chinese | ||
| 44579643 | 董事会战略委员会工作细则（草案） | 2026-04-07 | Chinese | ||
| 44579636 | 股东通讯政策（草案） | 2026-04-07 | Chinese | ||
| 44579629 | 迈威生物关于修订H股发行后适用的《公司章程》及公司部分治理制度的公告 | 2026-04-07 | Chinese | ||
| 44579622 | 股息政策（草案） | 2026-04-07 | Chinese | ||
| 44579619 | 股东会议事规则（草案） | 2026-04-07 | Chinese | ||
| 44579616 | 关联（连）交易管理制度（草案） | 2026-04-07 | Chinese | ||
| 44579602 | 迈威生物关于刊发H股发行聆讯后资料集的公告 | 2026-04-02 | Chinese | ||
| 44579592 | 国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司首次公开发行股票并上市之保荐总结报告书 | 2026-03-31 | Chinese | ||
| 44579577 | 国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2025年度持续督导年度跟踪报告 | 2026-03-31 | Chinese | ||
| 44579568 | 国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2025年度持续督导现场检查报告 | 2026-03-30 | Chinese | ||
| 44579566 | 迈威生物关于重新向香港联交所递交H股发行并上市的申请并刊发申请资料的公告 | 2026-03-25 | Chinese | ||
| 44579561 | 安永华明会计师事务所（特殊普通合伙）关于迈威（上海）生物科技股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告 | 2026-03-24 | Chinese | ||
| 44579560 | 迈威生物2026年度”提质增效重回报”行动方案 | 2026-03-24 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58111/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58111 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58111 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58111 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58111}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. (id: 58111)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.